- Home
- AORT
AORT
Artivion Inc.
as 07-26-2024 4:00pm EST
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | KENNESAW |
| Market Cap: | 992.4M | IPO Year: | 1993 |
| Target Price: | $28.33 | AVG Volume (30 days): | 339.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.16 - $29.24 | Next Earning Date: | 08-08-2024 |
| Revenue: | $368,206,000 | Revenue Growth: | 15.13% |
| Revenue Growth (this year): | 12.74% | Revenue Growth (next year): | 9.75% |
Stock Insider Trading Activity of Artivion Inc. (AORT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Holloway Jean F | AORT | SVP, General Counsel | May 10 '24 | Sell | $23.42 | 1,250 | $29,275.13 | 167,482 | SEC Form 4 |
| Holloway Jean F | AORT | SVP, General Counsel | May 9 '24 | Sell | $23.79 | 979 | $23,285.52 | 168,732 | SEC Form 4 |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Mar 20 '24 | Sell | $20.39 | 2,183 | $44,511.37 | 83,296 | SEC Form 4 |
| GREEN ANDREW M | AORT | VP Regulatory | Mar 15 '24 | Sell | $20.00 | 1,462 | $29,240.00 | 41,121 | SEC Form 4 |
| GREEN ANDREW M | AORT | VP Regulatory | Mar 14 '24 | Sell | $20.00 | 3,994 | $79,880.00 | 42,583 | SEC Form 4 |
| Getz Matthew A | AORT | VP, Human Resources | Mar 12 '24 | Sell | $19.94 | 5,000 | $99,719.50 | 43,536 | SEC Form 4 |
| Horton Amy | AORT | VP, Chief Accounting Officer | Mar 1 '24 | Sell | $18.72 | 1,152 | $21,568.09 | 139,989 | SEC Form 4 |
| Getz Matthew A | AORT | VP, Human Resources | Mar 1 '24 | Sell | $18.72 | 1,157 | $21,661.35 | 48,536 | SEC Form 4 |
| Mackin James P | AORT | President & CEO | Mar 1 '24 | Sell | $18.72 | 13,996 | $262,037.31 | 706,038 | SEC Form 4 |
| Mackin James P | AORT | President & CEO | Mar 1 '24 | Sell | $18.72 | 13,996 | $262,037.31 | 705,562 | SEC Form 4 |
| Holloway Jean F | AORT | SVP, General Counsel | Mar 1 '24 | Sell | $18.72 | 2,380 | $44,558.84 | 169,669 | SEC Form 4 |
| Davis John E | AORT | Chief Commercial Officer | Mar 1 '24 | Sell | $18.72 | 2,022 | $37,856.29 | 165,637 | SEC Form 4 |
| Davis John E | AORT | Chief Commercial Officer | Mar 1 '24 | Sell | $18.72 | 2,022 | $37,856.29 | 165,690 | SEC Form 4 |
| Getz Matthew A | AORT | VP, Human Resources | Mar 1 '24 | Sell | $18.72 | 1,157 | $21,661.35 | 48,503 | SEC Form 4 |
| Maney Rochelle L. | AORT | VP, Quality | Mar 1 '24 | Sell | $18.72 | 1,157 | $21,661.82 | 46,536 | SEC Form 4 |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Mar 1 '24 | Sell | $18.72 | 1,506 | $28,195.48 | 85,479 | SEC Form 4 |
| Maney Rochelle L. | AORT | VP, Quality | Mar 1 '24 | Sell | $18.72 | 1,157 | $21,661.82 | 46,569 | SEC Form 4 |
| Holloway Jean F | AORT | SVP, General Counsel | Mar 1 '24 | Sell | $18.72 | 2,380 | $44,558.84 | 169,711 | SEC Form 4 |
| GREEN ANDREW M | AORT | VP Regulatory | Mar 1 '24 | Sell | $18.72 | 1,160 | $21,717.64 | 46,541 | SEC Form 4 |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Mar 1 '24 | Sell | $18.72 | 1,506 | $28,195.48 | 85,438 | SEC Form 4 |
| Horton Amy | AORT | VP, Chief Accounting Officer | Mar 1 '24 | Sell | $18.72 | 1,152 | $21,568.09 | 139,957 | SEC Form 4 |
| GREEN ANDREW M | AORT | VP Regulatory | Mar 1 '24 | Sell | $18.72 | 1,160 | $21,717.64 | 46,577 | SEC Form 4 |
| Getz Matthew A | AORT | VP, Human Resources | Feb 27 '24 | Sell | $19.83 | 325 | $6,446.18 | 46,082 | SEC Form 4 |
| Mackin James P | AORT | President & CEO | Feb 27 '24 | Sell | $19.83 | 4,837 | $95,938.99 | 691,416 | SEC Form 4 |
| Horton Amy | AORT | VP, Chief Accounting Officer | Feb 27 '24 | Sell | $19.83 | 325 | $6,446.18 | 137,531 | SEC Form 4 |
Latest Artivion Inc. News
AORT Breaking Stock News: Dive into AORT Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
Argus Research
3 days ago
AORT: Raising target price to $29.00
Argus Research
10 days ago
AORT: Rating increased to a HOLD
Argus Research
17 days ago
AORT: What does Argus have to say about AORT?
PR Newswire
25 days ago
Artivion Amends Agreements with Endospan
Simply Wall St.
a month ago
Artivion's (NYSE:AORT) Returns Have Hit A Wall
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare AORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AORT Artivion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.